Related Experiment Videos
Diagnosis and treatment of pulmonary artery hypertension
1Columbia-Presbyterian Medical Center, Babies Hospital, New York, NY 10032, USA.
Insights
While pulmonary artery hypertension remains incurable, recent medical and surgical advances significantly improve outcomes for affected children. New therapies enhance quality of life, exercise capacity, and survival rates.
Area of Science:
- Pediatric Cardiology
- Pulmonary Hypertension Research
Background:
- Pulmonary artery hypertension (PAH) in children presents a significant clinical challenge with no current cure.
- Despite the lack of a cure, therapeutic progress has markedly improved patient outcomes over the last decade.
Purpose of the Study:
- To review the diagnostic work-up and evaluation of pediatric pulmonary hypertension.
- To discuss recent therapeutic advances and their impact on managing childhood pulmonary hypertension.
Main Methods:
- Review of current literature on pediatric pulmonary hypertension diagnosis and treatment.
- Discussion of established and emerging therapeutic modalities.
Main Results:
- Therapeutic advances have led to significant improvements in quality of life for children with PAH.
- Enhanced exercise capacity, improved pulmonary hemodynamics, and increased long-term survival have been observed.
Conclusions:
- While a cure for pulmonary artery hypertension is not yet available, current treatments offer substantial benefits for affected children.
- Ongoing therapeutic strategies, including anticoagulation, vasodilator therapy, and transplantation, are crucial for managing pediatric pulmonary hypertension.
Abstract:
It is intellectually unsatisfying for physicians to admit that a group of patients remain for whom no cure is available in modern medicine. Despite our inability to cure pulmonary artery hypertension, therapeutic medical and surgical advances over the past decade have resulted in significant improvements in the outcome for children with various forms of pulmonary hypertension. This review discusses the work-up and evaluation of a child who presents with pulmonary artery hypertension and discusses recent therapeutic advances. The roles of anticoagulation, vasodilator therapy (including inhaled nitric oxide and chronic intravenous prostacyclin), and transplantation are discussed. These therapeutic modalities have improved quality of life, exercise capacity, and pulmonary hemodynamics as well as long-term survival for children with pulmonary hypertension.